BRAF (V600K)
Sign in to save this workspaceBRAF · Variant type: point · HGVS: p.V600K
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ripretinib | 100.0% | 0.0% | 92.95 |
| 2 | Dabrafenib | 99.7% | 0.3% | 94.74 |
| 3 | Encorafenib | 99.2% | 0.8% | 98.50 |
| 4 | Sorafenib | 98.5% | 1.5% | 96.72 |
| 5 | Regorafenib | 98.4% | 1.6% | 95.99 |
| 6 | Apatinib | 98.4% | 1.6% | 97.73 |
| 7 | Nilotinib | 98.1% | 1.9% | 96.49 |
| 8 | Umbralisib | 98.0% | 2.0% | 98.74 |
| 9 | Vemurafenib | 97.3% | 2.7% | 96.49 |
| 10 | Ponatinib | 97.2% | 2.8% | 78.23 |
| 11 | Pazopanib | 94.3% | 5.7% | 97.49 |
| 12 | Dasatinib | 92.4% | 7.6% | 87.97 |
| 13 | Erdafitinib | 89.5% | 10.5% | 95.71 |
| 14 | Upadacitinib | 86.4% | 13.6% | 97.98 |
| 15 | Tivozanib | 83.9% | 16.1% | 92.42 |
| 16 | Rabusertib | 82.9% | 17.1% | 98.74 |
| 17 | Imatinib | 76.2% | 23.8% | 99.00 |
| 18 | Ibrutinib | 61.0% | 39.0% | 94.74 |
| 19 | Acalabrutinib | 55.9% | 44.1% | 99.50 |
| 20 | Pacritinib | 54.7% | 45.3% | 88.64 |
| 21 | Deucravacitinib | 54.1% | 45.9% | 98.99 |
| 22 | Afatinib | 53.1% | 46.9% | 98.50 |
| 23 | Vandetanib | 45.5% | 54.5% | 95.74 |
| 24 | Canertinib | 44.0% | 56.0% | 96.49 |
| 25 | Lenvatinib | 42.6% | 57.4% | 97.74 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ripretinib | 100.0% | 100.0% | +0.0% |
| Dabrafenib | 99.7% | 98.3% | +1.4% |
| Encorafenib | 99.2% | 98.0% | +1.2% |
| Sorafenib | 98.5% | 98.5% | -0.1% |
| Regorafenib | 98.4% | 98.3% | +0.1% |
| Apatinib | 98.4% | 94.1% | +4.3% |
| Nilotinib | 98.1% | 85.8% | +12.3% |
| Umbralisib | 98.0% | 65.3% | +32.8% |
| Vemurafenib | 97.3% | 92.8% | +4.4% |
| Ponatinib | 97.2% | 99.4% | -2.2% |
| Pazopanib | 94.3% | 79.3% | +15.0% |
| Dasatinib | 92.4% | 80.6% | +11.8% |
| Erdafitinib | 89.5% | 54.1% | +35.4% |
| Upadacitinib | 86.4% | 49.6% | +36.7% |
| Tivozanib | 83.9% | 41.8% | +42.1% |
| Rabusertib | 82.9% | 41.1% | +41.9% |
| Imatinib | 76.2% | — | — |
| Ibrutinib | 61.0% | — | — |
| Acalabrutinib | 55.9% | — | — |
| Pacritinib | 54.7% | 58.5% | -3.8% |
| Deucravacitinib | 54.1% | — | — |
| Afatinib | 53.1% | — | — |
| Vandetanib | 45.5% | — | — |
| Canertinib | 44.0% | 40.7% | +3.3% |
| Lenvatinib | 42.6% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| Skin Cancer | Skin | ref |
| Colon/Colorectal Cancer | Large Intestine | ref |
| malignant_melanoma_skin | Skin | ref |
| malignant_melanoma_NS | Skin | ref |
| carcinoma_biliary_tract | Biliary Tract | ref |
| glioma_central_nervous_system | Brain/CNS | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| benign_melanocytic_nevus_skin | Skin | ref |
| other_central_nervous_system | Brain/CNS | ref |
| malignant_melanoma_eye | Brain/CNS | ref |
| MELA-AU | Skin | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.7ms